ARTICLE | Finance
BioCentury’s Financial Report also includes new biotech foundry Jupiter, and public equity fundings for Spyre, Cidara and Aclaris
By Paul Bonanos, Director of Biopharma Intelligence
November 23, 2024 2:09 AM UTC
EQT and Merck’s venture arm joined local Belgian investors in a round for antibody developer ABT that ranks as the fourth-largest series A for a biotech start-up in Belgium, according to BioCentury’s BCIQ database.
The €54 million ($57 million) round will allow ABT Therapeutics Inc. to develop of a pipeline of “weaponized” antibodies that incorporate targeting and killing domains. Unlike traditional antibody-drug conjugates, the company’s ATBody products deploy peptide payloads rather than chemotherapy molecules to destroy cancer cells; they can also be designed to treat autoimmune diseases…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654294/atb-s-54m-series-a-among-largest-ever-in-belgium